US5334582A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical bacteriocin compositions and methods for using the same
Assignee: Applied Microbiology Inc
•
Filing: 1993-07-06
•
Granted: 1994-08-02
•
Expires: 2013-07-06
Abstract
Abstract Compositions comprising lanthionine-containing bacteriocins such as nisin in combination with a chelator act as bactericides in low pH environments. In a preferred embodiment pharmaceutical preparations containing the compositions are used for the control of bacteria responsible for disorders of the gastrointestinal tract.
Inventors
- 👤 Peter Blackburn
- 👤 Steven J. Projan
- 👤 Edward B. Goldberg
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 10:00
CPC Classifications
A; A61; A61Q; A61Q11/00; A01; A01N; A01N37/00; A01N37/44; A01N37/46; A01N63/00; A01N63/50; A23; A23B; A23B11/00; A23B11/60; A23B11/65; A23B11/67; A23B2/00; A23B2/70; A23B2/725; A23B2/729; A23B2/7295; A23B2/767; A23B2/783; A23C; A23C9/00; A23C9/152; A23C9/158; A23C9/1585; A61K; A61K38/00; A61K38/16; A61K38/164; A61K8/00; A61K8/18; A61K8/30; A61K8/33; A61K8/37; A61K8/375; A61K8/40; A61K8/41; A61K8/416; A61K8/44; A61K8/64; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 34
Claim 1
Independent Claim
39 words
A method of preventing or treating for bacterial infection in a low-pH environment in the range of pH 2-5 comprising contacting the bacteria with a composition comprising a lanthionine-containing bacteriocin and a chelating agent in a pharmaceutically acceptable carrier.
Claim 2
Independent Claim
39 words
A method of preventing or treating for bacterial infection in a low-pH environment in the range of pH 2-5 comprising contacting the bacteria with a composition comprising a lanthionine-containing bacteriocin and a chelating agent in a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim
11 words
The method of claim 1 wherein the chelating agent is citrate.
Claim 4
Dependent Claim
11 words
The method of claim 1 wherein the chelating agent is EDTA.
Claim 5
Dependent Claim
13 words
The method of claim 1 wherein the chelating agent comprises citrate and EDTA.
Claim 6
Dependent Claim
14 words
A method of claim 1 wherein the composition also contains acetate, succinate or lactate.
Claim 7
Dependent Claim
25 words
The method of claim 1, wherein the bacteriocin is selected from the group consisting of nisin, subtilin, epidermin, Pep 5, ancovenin, gallidermin, duromycin or cinnamycin.
Claim 8
Dependent Claim
15 words
The method of claim 1 wherein the bacteriocin is nisin and the chelator is citrate.
Claim 9
Dependent Claim
13 words
The method of claim 1, wherein the composition also comprises an acid vehicle.
Claim 10
Dependent Claim
28 words
The method of claim 8, wherein the acid vehicle is selected from the group consisting of acetate, propionate, citrate, lactate, succinate, fumarate, malonate, adipate, sorbate, phosphate, or ascorbate.
Claim 11
Independent Claim
29 words
A method of preventing or treating a bacterial infection in the gastrointestinal tract comprising administering into the gastrointestinal tract a composition comprising a lanthionine-containing bacteriocin and a chelating agent.
Claim 12
Independent Claim
29 words
A method of preventing or treating a bacterial infection in the gastrointestinal tract comprising administering into the gastrointestinal tract a composition comprising a lanthionine-containing bacteriocin and a chelating agent.
Claim 13
Dependent Claim
11 words
The method of claim 10, wherein the lanthionine-containing bacteriocin is nisin.
Claim 14
Dependent Claim
11 words
The method of claim 10 wherein the chelating agent is citrate.
Claim 15
Dependent Claim
12 words
The method of claim 10 wherein the bacteria are gram negative bacteria.
Claim 16
Independent Claim
34 words
A method of treating gastrointestinal disorders in mammals due to the presence of Escherichia coli bacteria comprising contacting the bacteria with a composition comprising nisin and a chelating agent in a pharmaceutically acceptable carrier.
Claim 17
Independent Claim
34 words
A method of treating gastrointestinal disorders in mammals due to the presence of Escherichia coli bacteria comprising contacting the bacteria with a composition comprising nisin and a chelating agent in a pharmaceutically acceptable carrier.
Claim 18
Independent Claim
34 words
A method of treating gastrointestinal disorders in mammals due to the presence of Helicobacter pylori bacteria comprising contacting the bacteria with a composition comprising nisin and a chelating agent in a pharmaceutically acceptable carrier.
Claim 19
Independent Claim
34 words
A method of treating gastrointestinal disorders in mammals due to the presence of Helicobacter pylori bacteria comprising contacting the bacteria with a composition comprising nisin and a chelating agent in a pharmaceutically acceptable carrier.
Claim 20
Independent Claim
33 words
A method of treating gastrointestinal disorders in mammals due to the presence of Salmonella bacteria comprising contacting the bacteria with a composition comprising nisin and a chelating agent in a pharmaceutically acceptable carrier.
Claim 21
Independent Claim
33 words
A method of treating gastrointestinal disorders in mammals due to the presence of Salmonella bacteria comprising contacting the bacteria with a composition comprising nisin and a chelating agent in a pharmaceutically acceptable carrier.
Claim 22
Dependent Claim
30 words
A pharmaceutical composition useful for treating gastrointestinal disorders due to gram negative bacteria comprising a suitable amount of nisin, a chelating agent, an acid vehicle, and a pharmaceutically acceptable carrier.
Claim 23
Dependent Claim
30 words
A pharmaceutical composition useful for treating gastrointestinal disorders due to gram negative bacteria comprising a suitable amount of nisin, a chelating agent, an acid vehicle, and a pharmaceutically acceptable carrier.
Claim 24
Dependent Claim
18 words
The pharmaceutical composition of claim 17 wherein the chelating agent is EDTA and the acid vehicle is citrate.
Claim 25
Dependent Claim
29 words
A pharmaceutical composition useful for treating gastrointestinal disorders due to microorganisms comprising an effective amount of a lanthionine-containing bacteriocin, a chelator, an acid vehicle and a pharmaceutically acceptable carrier.
Claim 26
Dependent Claim
29 words
A pharmaceutical composition useful for treating gastrointestinal disorders due to microorganisms comprising an effective amount of a lanthionine-containing bacteriocin, a chelator, an acid vehicle and a pharmaceutically acceptable carrier.
Claim 27
Dependent Claim
25 words
The composition of claim 19, wherein the bacteriocin is selected from the group consisting of nisin, subtilin, epidermin, Pep 5, ancovenin, gallidermin, duromycin or cinnamycin.
Claim 28
Dependent Claim
14 words
The composition of claim 20, wherein the chelator and the acid vehicle are citrate.
Claim 29
Dependent Claim
16 words
The composition of claim 21, wherein the chelator is EDTA and the acid vehicle is citrate.
Claim 30
Independent Claim
39 words
A method for inhibiting the growth of or killing bacteria in a low-pH environment in the range of pH 2-5 comprising contacting the bacteria with a composition comprising a lanthionine-containing bacteriocin and a chelating agent in a suitable carrier.
Claim 31
Independent Claim
39 words
A method for inhibiting the growth of or killing bacteria in a low-pH environment in the range of pH 2-5 comprising contacting the bacteria with a composition comprising a lanthionine-containing bacteriocin and a chelating agent in a suitable carrier.
Claim 32
Dependent Claim
11 words
The method of claim 23 wherein the bacteria are gram negative.
Claim 33
Dependent Claim
10 words
The method of claim 23 wherein the bacteriocin is nisin.
Claim 34
Independent Claim
14 words
The method of any one of claims 23-25 wherein the pH range is 2-4.
References Cited (Backward Citations)
US2744827A
Cited
GB738655A
Cited
US3579354A
Cited
US3899594A
Cited
US3988307A
Cited
US4158607A
Cited
US4318928A
Cited
US4477471A
Cited
US4584199A
Cited
US4597972A
Cited
US4716115A
Cited
US4485029A
Cited
WO1989012399A1
Cited
EP0384319A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-08-01 | 1998-01-31 | 1998-08-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-08-01 | 2002-01-31 | 2002-08-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-08-01 | 2006-01-31 | 2006-08-02 | $7700.00 | Window Closed / Lapsed |